当前位置：
X-MOL 学术
›
N. Engl. J. Med.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer
The New England Journal of Medicine ( IF 158.5 ) Pub Date : 2017-11-01 , DOI: 10.1056/nejmc1711644
The New England Journal of Medicine ( IF 158.5 ) Pub Date : 2017-11-01 , DOI: 10.1056/nejmc1711644
To the Editor: In this trial involving women with metastatic breast cancer and a BRCA mutation, Robson et al. (Aug. 10 issue)1 randomly assigned patients to receive olaparib or standard therapy. A total of 46% of patients in the olaparib group and 47% in the standard-therapy group died (hazard ratio, 0.90; 95% confidence interval, 0.63 to 1.29). This trial is presented as a major advance in the Journal and in the popular press.2 As is common practice in trials of treatment for metastatic breast cancer, the primary end point was progression-free survival, for which the results were favorable; however, time . . .
更新日期：2017-11-02
京公网安备 11010802027423号